KPTI, US48576U2050

Karyopharm Therapeutics stock falls 13.72 percent as liquidity tightens

Published on 10/05/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Karyopharm Therapeutics stock faces a USD 15.8 million debt deadline on October 15, 2026. Q2 revenue fell to USD 33.4 million from USD 37.9 million, while consensus remains Buy.

KPTI, US48576U2050, Illustration mit AI erstellt.

Karyopharm Therapeutics stock (ISIN US48576U2050) fell 13.72 percent to USD 0.69 on Nasdaq at 3:27 p.m. ET on October 5, 2026, as liquidity concerns continued to dominate the biotech story. The company has a forbearance deadline on October 15, 2026, while its latest quarterly figures show falling revenue and a deep net loss.

Liquidity deadline sets the tone

According to TipRanks on September 10, 2026, Karyopharm entered a forbearance agreement after missing a USD 15.8 million term-loan installment and certain interest payments. The arrangement is scheduled to end by October 15, 2026, leaving financing, a strategic transaction or creditor support as the key balance-sheet variables.

The company also agreed to pay USD 20.0 million in creditor fees through newly issued convertible preferred stock, according to TipRanks. That structure adds a potential dilution factor at a time when the equity value is already compressed.

Revenue falls while losses widen

Karyopharm reported Q2 2026 revenue of USD 33.4 million, compared with USD 37.9 million in Q2 2025, a decline of 11.9 percent, according to Yahoo Finance. U.S. XPOVIO net product revenue increased to USD 30.8 million from USD 29.7 million, but the company still posted a net loss of USD 67.0 million for the quarter.

The same Q2 2026 earnings transcript said Karyopharm ended June with USD 65.4 million in cash equivalents, restricted cash and investments. For investors, the contrast between commercial product revenue and cash needs is central: the marketed oncology business generated sales, while financing pressure remained the immediate valuation issue.

Consensus target stays far above price

The published consensus is Buy, based on 13 Buy, 5 Hold and 2 Sell ratings, with a median price target of USD 9.50 and a range of USD 3.00 to USD 16.00, according to Paasa. The median target lies 1,276.8 percent above the USD 0.69 trading price, a gap that reflects both clinical upside expectations and severe execution risk.

Karyopharm describes itself as a commercial-stage pharmaceutical company focused on cancer therapies, with XPOVIO and a pipeline spanning multiple myeloma, endometrial cancer and myelofibrosis, according to its investor and media center. The company submitted a supplemental application for selinexor plus ruxolitinib in myelofibrosis on August 31, 2026, making regulatory progress another counterweight to the funding strain.

Stock trades near yearly low

Karyopharm Therapeutics stock was trading at USD 0.69 on Nasdaq on October 5, 2026, with a session range of USD 0.63 to USD 0.80 and volume of 1,744,877 shares. Its 52-week range was USD 0.63 to USD 10.99, while market capitalization stood at USD 15.7 million on the same date.